- Trials with a EudraCT protocol (108)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
108 result(s) found for: Amyotrophic Lateral Sclerosis (ALS).
Displaying page 4 of 6.
EudraCT Number: 2008-003982-21 | Sponsor Protocol Number: P080402 | Start Date*: 2010-06-10 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Etude des transporteurs de la dopamine et de la sérotonine en imagerie TEMP utilisant les radiopharmaceutiques 123I-FP-CIT (datscan) and 123 I-ADAM dans la sclérose latérale amyotrophique et dans u... | |||||||||||||
Medical condition: Patients présentant une SLA et volontaires sains | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002390-23 | Sponsor Protocol Number: XRP4274E/4101 | Start Date*: 2004-11-24 | |||||||||||
Sponsor Name:Aventis Pharma Ltd. | |||||||||||||
Full Title: Evaluation of the pharmacokinetic profile of Riluzole (XRP4274) and RPR112512 following multiple oral administrations of XRP4274 for 8 days in healthy Japanese and Caucasian male subjects | |||||||||||||
Medical condition: amyotrophic lateral sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-003707-32 | Sponsor Protocol Number: P080401 | Start Date*: 2008-10-09 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Etude de l'effet du carbonate de lithium sur une population de patients atteints de SLA en ouvert en comparaison avec une population de référence. LISLA | |||||||||||||
Medical condition: Patient atteint de sclérose latérale amyotrophique. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000250-26 | Sponsor Protocol Number: A35-004 | Start Date*: 2021-10-27 | |||||||||||
Sponsor Name:Amylyx Pharmaceuticals Inc. | |||||||||||||
Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic L... | |||||||||||||
Medical condition: ALS (amyotrophic lateral sclerosis) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) BE (Trial now transitioned) FR (Trial now transitioned) SE (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005413-23 | Sponsor Protocol Number: CY4031 | Start Date*: 2016-05-20 | |||||||||||
Sponsor Name:Cytokinetics, Inc. | |||||||||||||
Full Title: A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients with Amyotroph... | |||||||||||||
Medical condition: Amyotrophic Lateral Sclerosis (ALS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) IE (Completed) NL (Completed) ES (Completed) PT (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003962-38 | Sponsor Protocol Number: RT001-014 | Start Date*: 2021-02-02 | |||||||||||
Sponsor Name:Retrotope, Inc. | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO ASSESS EFFICACY, LONG TERM SAFETY AND TOLERABILITY OF RT001 IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS | |||||||||||||
Medical condition: Amyotrophic Lateral Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) SE (Completed) NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-006254-85 | Sponsor Protocol Number: CeTMad/ELA/2011 | Start Date*: 2013-02-08 | |||||||||||
Sponsor Name:FUNDACIÓN PROGRESO Y SALUD | |||||||||||||
Full Title: Placebo controlled, randomized and triple blind multicentric phase I/II clinical trial to evaluate the safety, feasibility and valoration of efficacy trends of intravenous administration of three d... | |||||||||||||
Medical condition: Amyotrophic lateral sclerosis (ALS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002629-13 | Sponsor Protocol Number: CY4033 | Start Date*: 2017-02-28 | |||||||||||
Sponsor Name:Cytokinetics, Inc. | |||||||||||||
Full Title: A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients with Amyotrophic Lateral Sclerosis (ALS) who Completed VITALITY-ALS (CY 4031) | |||||||||||||
Medical condition: Amyotrophic Lateral Sclerosis (ALS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) ES (Completed) NL (Completed) BE (Completed) PT (Completed) FR (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000826-22 | Sponsor Protocol Number: CBLZ945C12201 | Start Date*: 2019-09-17 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: An open-label, adaptive design study in patients with amyotrophic lateral sclerosis (ALS) to characterize safety, tolerability and brain microglia response, as measured by TSPO binding, following m... | |||||||||||||
Medical condition: Amyotrophic lateral sclerosis (ALS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) FI (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002185-32 | Sponsor Protocol Number: NST003 | Start Date*: 2022-11-21 | |||||||||||
Sponsor Name:NeuroSense Therapeutics Ltd | |||||||||||||
Full Title: A Phase IIb, Randomized, Multi-center, Multinational, Prospective, Double-Blind, Placebo- Controlled Study, with an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in ... | |||||||||||||
Medical condition: Amyotrophic lateral sclerosis (ALS) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004171-12 | Sponsor Protocol Number: ALSTEM | Start Date*: 2020-07-22 | |||||||||||
Sponsor Name:Polski Bank Komórek Macierzystych JSC (PBKM) | |||||||||||||
Full Title: The evaluation of the effect of Wharton’s Jelly Mesenchymal Stem Cells (WJMSCs) on the immune system of patients with Amyotrophic Lateral Sclerosis (ALS) | |||||||||||||
Medical condition: Amyotrophic Lateral Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004567-21 | Sponsor Protocol Number: 3119001 | Start Date*: 2015-06-05 | |||||||||||
Sponsor Name:Orion Corporation Orion Pharma | |||||||||||||
Full Title: Effects of ODM-109 on respiratory function in patients with ALS. A randomised, double blind, placebo-controlled, cross-over, 3-period, multicentre study with open-label follow-up extension | |||||||||||||
Medical condition: Amyotrophic lateral sclerosis (ALS). A rapidly progressive neurological disease characterized by degeneration of upper and lower motor neurons with subsequent muscle atrophy and weakness and loss ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) DE (Completed) GB (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002267-29 | Sponsor Protocol Number: WVE-004-002 | Start Date*: 2022-10-14 | ||||||||||||||||
Sponsor Name:Wave Life Sciences UK Limited | ||||||||||||||||||
Full Title: A Multicenter, Open-label Extension (OLE) Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-004 in Patients with C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and... | ||||||||||||||||||
Medical condition: Amyotrophic Lateral Sclerosis and Frontotemporal Dementia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Prematurely Ended) IE (Completed) BE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-001989-38 | Sponsor Protocol Number: IMCRELA | Start Date*: 2021-07-08 | |||||||||||
Sponsor Name:Facultad de medicina y ciencias de la salud de la Universidad Católica de Valencia | |||||||||||||
Full Title: IMPACT OF THE COMBINED TREATMENT OF THE LIPOSOMATED POLYPHENOLS CÚRCULA AND RESVERATROL® WITH DUTASTERIDE, IN THE CLINICAL IMPROVEMENT OF PATIENTS WITH ALS TREATED WITH RILUZOLE | |||||||||||||
Medical condition: Amyotrophic Lateral Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006511-29 | Sponsor Protocol Number: PTC857-CNS-001-ALS | Start Date*: 2022-08-26 | |||||||||||
Sponsor Name:PTC Therapeutics, Inc. | |||||||||||||
Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK, AND BIOMARKER EFFECTS OF PTC857 IN ADULT SUBJECTS WITH AMYOTROPHIC LATERAL ... | |||||||||||||
Medical condition: Amyotrophic Lateral Sclerosis (ALS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) DE (Ongoing) BE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) PL (Trial now transitioned) NL (Ongoing) NO (Trial now transitioned) SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003225-41 | Sponsor Protocol Number: 233AS102 | Start Date*: 2017-04-10 | ||||||||||||||||
Sponsor Name:Biogen Idec Research Limited | ||||||||||||||||||
Full Title: An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB067 Administered to Previously Treated Adults with Amyotrophic Lateral Sc... | ||||||||||||||||||
Medical condition: Amyotrophic Lateral Sclerosis (ALS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) DE (Ongoing) DK (Completed) PL (Completed) ES (Prematurely Ended) IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001431-20 | Sponsor Protocol Number: CHDR1417 | Start Date*: 2015-08-17 | |||||||||||
Sponsor Name:Centre for Human Drug Research | |||||||||||||
Full Title: A randomized, double blind, double-dummy placebo controlled, 3-way cross-over study to determine the test-retest reliability of, and the effect of oral retigabine and riluzole on, peripheral motor ... | |||||||||||||
Medical condition: Amytrophic Lateral Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006891-31 | Sponsor Protocol Number: RAA/2008/013 | Start Date*: 2009-02-17 | |||||||||||
Sponsor Name:King's College London | |||||||||||||
Full Title: A randomised placebo-controlled trial of Lithium carbonate in Amyotrophic Lateral Sclerosis (LiCALS) | |||||||||||||
Medical condition: Amyotrophic Lateral Sclerosis (ALS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000142-18 | Sponsor Protocol Number: 1.0 | Start Date*: 2018-05-09 | |||||||||||
Sponsor Name:Turku University Hospital | |||||||||||||
Full Title: Feasibility and pharmacodynamics of subcutaneously given combination of dexmedetomidine and ketamine infusion in ALS patients receiving palliative care | |||||||||||||
Medical condition: Amyotrophic lateral sclerosis (ALS) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004098-33 | Sponsor Protocol Number: 233AS101 | Start Date*: 2016-06-29 | ||||||||||||||||
Sponsor Name:Biogen Idec Research Limited | ||||||||||||||||||
Full Title: A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIIB067 Administered to Adult Subjects with Amyotrophic Lateral Sclerosis and Confirmed Superoxide D... | ||||||||||||||||||
Medical condition: Amyotrophic Lateral Sclerosis (ALS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Prematurely Ended) DE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) DK (Completed) PL (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
